Scalper1 News
Bristol-Myers Squibb (BMY) was down more than 6% on the stock market today after the company’s latest cancer-drug data moved one analyst to downgrade the stock, though others saw little that was unexpected. Late Wednesday, the abstracts for various presentations at the upcoming American Society for Clinical Oncology (ASCO) meeting went online, including phase-two data on Bristol’s much-anticipated immuno-oncology candidate nivolumab in combination Scalper1 News
Scalper1 News